123 related articles for article (PubMed ID: 38376291)
1. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer.
Piracha ZZ; Saeed U
J Cancer Res Ther; 2023 Oct; 19(7):1870-1879. PubMed ID: 38376291
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
5. LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.
Faraz M; Tellström A; Ardnor CE; Grankvist K; Huminiecki L; Tavelin B; Henriksson R; Hedman H; Ljuslinder I
BMC Cancer; 2020 May; 20(1):459. PubMed ID: 32448168
[TBL] [Abstract][Full Text] [Related]
6. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract][Full Text] [Related]
7. The LRIG family: enigmatic regulators of growth factor receptor signaling.
Simion C; Cedano-Prieto ME; Sweeney C
Endocr Relat Cancer; 2014; 21(6):R431-43. PubMed ID: 25183430
[TBL] [Abstract][Full Text] [Related]
8. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
9. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
10. LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia.
Nagata M; Nakamura T; Sotozono C; Inatomi T; Yokoi N; Kinoshita S
PLoS One; 2014; 9(4):e93164. PubMed ID: 24709893
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Zhang X; Song Q; Wei C; Qu J
Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
[TBL] [Abstract][Full Text] [Related]
13. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
15. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
[TBL] [Abstract][Full Text] [Related]
16. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
17. Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.
An Y; Zhao Z; Ou P; Wang G
Medicine (Baltimore); 2015 Nov; 94(47):e2081. PubMed ID: 26632716
[TBL] [Abstract][Full Text] [Related]
18. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
19. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
20. LRIG1 is a prognostic biomarker in non-small cell lung cancer.
Kvarnbrink S; Karlsson T; Edlund K; Botling J; Lindquist D; Jirström K; Micke P; Henriksson R; Johansson M; Hedman H
Acta Oncol; 2015; 54(8):1113-9. PubMed ID: 25813475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]